Your Support Network

Get involved with the Alpha-1 community.

A wealth of resources and Alpha-1 peer support

Alpha-1 is a lifelong journey. The good news is you have help and support at every step. The Zemaira CareZ community is available to assist you. We also encourage you to get involved with the larger Alpha-1 community through the Alpha-1 Foundation, which is dedicated to supporting and advocating for Alphas and strongly supported by CSL Behring, the maker of Zemaira.

  • The Alpha-1 Foundation has worked closely with multiple agencies and the pharmaceutical industry to expedite the development of improved therapies. With the overriding goal of curing Alpha-1, the Alpha-1 Foundation has invested almost $47 million to support alpha-1 antitrypsin deficiency research and programs at 94 institutions in North America, Europe, the Middle East, and Australia.

Other helpful resources include:

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
ZMR14-04-0006d 12/2014